0002058707

IPO filing research

Attovia Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)

ipo amended Nasdaq Global Market S-1

Attovia Therapeutics, Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1 on 2026-07-14. Current deal snapshot: exchange Nasdaq Global Market.

Filing Timeline

SEC EDGAR

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Common Stock · Exchange Nasdaq Global Market · Ticker ATTO · Use of proceeds Proceeds will be used for general corporate purposes · Underwriters Morgan Stanley, Leerink Partners, Citigroup

Attovia Therapeutics, Inc. is conducting an IPO as outlined in its S-1 filing, detailing financials, risk factors, and capital structure adjustments. The company, an early-stage biopharmaceutical firm, has no approved products, significant operating losses, and relies on private equity financing. The filing includes adjustments to share counts, including preferred stock conversion to common stock and a reverse stock split, alongside pro forma financial data reflecting potential IPO outcomes.

2026-07-14 · 0001193125-26-303256

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

2026-06-05 · 0001193125-26-259800

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

2026-02-12 · 0001193125-26-048782

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

2025-12-19 · 0001193125-25-326945

Comparable Deals

16 comparable deals

Healthcare & BiotechLast 18 months

Only 0 strict matches; expanded to 16 using nearest neighbors.

Showing top 8 by similarity.

-1.3%

Median day-1

50%

Above issue

-1.3%

Median week-1

-20.9%

Downside (p10)

SL Science Holding Ltd SLBT

2026-06-15 - Day 1: -16.8% Wk 1: +13.0%

same SICrecent IPO

Odyssey Therapeutics, Inc. ODTX

2026-05-08 $279M Day 1: -8.8% Wk 1: -3.8%

same SICrecent IPO

Hemab Therapeutics Holdings, Inc. COAG

2026-05-01 $302M Day 1: +88.9% Wk 1: +43.0%

same SICrecent IPO

Kardigan, Inc. KARD

2026-06-18 $400M Day 1: +37.5% Wk 1: +41.1%

same SIC grouprecent IPO

Agomab Therapeutics NV AGMB

2026-02-06 $200M Day 1: -8.4% Wk 1: -2.1%

same SICrecent IPO

Eikon Therapeutics, Inc. EIKN

2026-02-05 $381M Day 1: -16.7% Wk 1: -19.5%

same SICrecent IPO

Parabilis Medicines, Inc. PBLS

2026-06-10 $670M Day 1: +58.0% Wk 1: +30.2%

same SIC grouprecent IPO

Seaport Therapeutics, Inc. SPTX

2026-05-01 $255M Day 1: +10.2% Wk 1: -13.9%

same SIC grouprecent IPO

Recent News

No recent news stored for this issuer.